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Summary A series of human embryo fibroblasts has previously been shown to display increasing resistance to
the antimetabolites methotrexate (MTX) and N-phosphonacetyl-L-aspartate (PALA) with increasing
tumorigenicity. This increased resistance was found to be further increased as a result of salvage pathway
activity for purine and pyrimidine biosynthesis. A similar pattern of increasing resistance paralleling increasing
tumorigenicity has now been shown to occur with 5-fluorouracil (5-FU), which is independent of salvage
pathway activity. The KMS normal cell line was found to be more sensitive to 5-FU than either the
immortalised KMST or tumorigenic KN-NM cell lines. Immunohistochemical analysis of the three cell lines
demonstrated high levels of p53 protein in the KMST and KN-NM cell lines, but undetectable p53 levels in
the KMS cell line. From these data it was hypothesised that a difference in p53 function may be causing the
difference in the patterns of sensitivity observed in the three cell lines. P53 is now believed to function as a
regulator of a GI to S cell cycle checkpoint and as an inducer of apoptosis following DNA damage to the cell.
The differences in sensitivity of the cell lines could not be explained by differences in the levels ofapoptosis but
could be attributed to differences in cell cycle response. Our evidence suggests that loss of cell cycle control,
possibly through loss of p53 function, is an important factor in increasing the drug resistance of fibroblast cell
lines.
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The resistance of tumour cells to chemotherapeutic agents is
a major clinical problem in the treatment of human malig-
nancy. Many mechanisms of resistance have been postulated
and studied (Fox et al., 1991). In the past, resistance of
tumour cells to certain members of the antimetabolite group
of drugs has been attributed to either gene amplification
(Schimke et al., 1977; Wahl et al., 1979) or the increased
activity of the salvage pathways for purine and pyrimidine
biosynthesis (Weber 1983; Kinsella and Haran, 1991).
In fact previous work from this group has demonstrated
differences in the sensitivity of series of human embryo
fibroblast cell lines of common genetic origin, to the
chemotherapeutic antimetabolites methotrexate (MTX) and
N-phosphonacetyl-L-aspartate (PALA). This sensitivity could
be greatly decreased by the activity of the salvage pathways
for purine and pyrimidine biosynthesis (Kinsella and Haran,
1991; Pickard and Kinsella, 1995). A similar pattern of resis-
tance was observed with 5-fluorouracil (5-FU), with the
KMS normal cell line being more sensitive than either the
KMST or KN-NM cell lines. However, the increased resis-
tance of the KMST and KN-NM cell lines to 5-FU was
shown to be unaltered in the presence of the nucleoside
transport inhibitor dipyridamole (Pickard and Kinsella, 1995)
and thus was independent of salvage pathway involvement.
Progression towards the tumour phenotype results from
the interaction of dominantly acting oncogenes and tumour-
suppressor genes. It is becoming increasingly clear that the
cytotoxic action of many anti-cancer drugs involves processes
downstream of the interaction between a particular drug and
its target. It has been postulated that the outcome of drug
therapy is determined by the response of a particular cell
according to its phenotype, rather than by the nature of the
primary drug-target interaction alone (Dive and Hickman,
1991).
Alterations in p53 are the most common genetic aberra-
tions found so far in human malignancies (Hollstein et al.,
1991; Levine et al., 1991). P53 protein levels are not normally
detectable by immunohistochemical techniques, owing to the
relatively short half-life of the p53 protein in the cell nucleus
(Finlay et al., 1988). It is only when the p53 protein becomes
stabilised or overexpressed that the protein becomes detec-
table immunohistochemically. Stabilised p53 is now thought
to reflect a change in the environment of the cell which
affects, either directly or indirectly, the p53 protein and
indicates an inactivated or impaired function in that partic-
ular cell. The tumour-suppressor gene p53 protein product is
believed to serve as a critical regulator of a GI cell cycle
checkpoint and as an inducer of apoptosis following
exposure of cells to DNA-damaging agents (Katsan et al.,
1991; Fritsche et al., 1993; Nelson and Kastan, 1994). DNA
damaging agents, including those used in cancer chemo-
therapy, have been reported to induce nuclear accumulation
of wild-type p53 in fibroblasts of both mouse and human
origin (Lowe and Ruley 1993; Fritsche et al., 1993), causing
GI arrest, allowing repair processes to operate or, in severe
cases of DNA damage, initiation of apoptosis. It has been
suggested that DNA strand breaks are the necessary trigger
for the p53-dependent DNA damage response pathway (Nel-
son and Kastan, 1994). Human haematopoietic cells with
mutant p53 function do not exhibit GI arrest after DNA
damage and progress through the cell cycle (Kastan et al.,
1991,; Kuerbitz et al., 1992). Cells with mutant p53 function
will continue to proliferate regardless of the insult and will
not undergo apoptosis unless mitotic failure occurs as a
result of excessive DNA damage (Lane, 1992). Recently
immature mouse thymocytes lacking p53 have been shown
not to undergo apoptosis when exposed to ionising radiation
and demonstrate increased resistance to these lethal effects
(Lowe et al., 1993a). Studies in certain human tumour cells
lacking p53 have also demonstrated increased resistance to
ionising radiation as a result of the loss of GI checkpoint
control (Mcllwrath et al., 1994; Lee and Bernstein, 1993).
It has been postulated that it is the ability or failure of a
cancer cell to undergo apoptosis which is an important deter-
minant of the therapeutic response of that cell to insult (Dive
and Hickman, 1991; Lowe et al., 1993b). Chemotherapeutic
agents including 5-FU along with irradiation and certain
hormonal therapies are known to induce apoptosis or prog-
rammed cell death in certain cell types (Dive and Hickman,
1991; Lowe et al., 1993b). Apoptosis is a genetically cont-
rolled cell deletion process that regulates organ development
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and tissue maintenance in rapidly proliferating tissues (Raff,
1992) and protects against cancer (Williams, 1991). Genes
known to participate in the regulation of apoptosis are EIA
(Rao et al., 1992; White et al., 1992; Lowe and Ruley 1993),
myc (Evan et al., 1992), bcl-2 (Hockenberry et al., 1990;
Chiou et al., 1994), p53 (Lowe et al., 1993a; Clarke et al.,
1993) and possibly ras.
In the present study we have investigated the difference in
resistance observed between the cell lines to 5-FU and tried
to establish the basis of this difference. Whether the
differences are a result of differing p53 functionality causing
differences in apoptosis levels or cell cycle arrest will be
discussed along with its implications for malignancy.
Materials and methods
Cell lines
The cell lines used were the normal human embryo fibroblast
cell line KMS-6, its cobalt-60-irradiated immortalised der-
ivative KMST (Namba et al., 1988) and the tumorigenic cell
line KN-NM established from the KMST cell line by trans-
fection with an activated N-ras oncogene cDNA (Kinsella et
al., 1990). This series of cell lines was chosen as a model for
the progression of a normal cell towards tumorigenicity as is
observed in vivo. All cell lines were routinely maintained in
monolayer culture in Dulbecco's modified Eagle medium
(Life Technologies, Paisley, UK) supplemented with 10%
fetal bovine serum (ICN Biomedicals, Irvine, UK) and
200 mM glutamine at 37TC in a humid atmosphere of 5%
carbon dioxide/95% air. Cells were routinely plated at a
density of 5 x 105 per 75 cm2 tissue culture flask in 10 ml of
medium and passaged approximately every 5 days by tryp-
sinisation.
Clonogenic cell survival assays
To assay for drug resistance (sensitivity) 500 test cells were
plated onto a feeder layer of 5 x 104 gamma-irradiated
(5000 rad) EJ human bladder carcinoma cells in a 1O cm
tissue culture plate (5 plates per point) and allowed to attach
for 4 h. These cell densities were established from preliminary
experiments and reflect plating efficiencies over the range of
12.3% (KMS) to 26% (KMST and KN-NM) in control
plates. After 4 h the medium was removed and replaced with
medium containing 5-FU at the appropriate concentration
over the range 1 x l0-7 to 1 x l0-4 M. The medium was
replaced with drug-free medium after weeks 1 and 2. The
plates were incubated for a total of 3 weeks to permit colony
formation. After 3 weeks the medium was removed and any
colonies present were fixed in ice-cold methanol for 15min
and stained with 10% Giemsa stain. Colonies were counted
and the colonies on the treated plates were expressed as a
percentage of the colonies on control plates to which no drug
had been added. These assays were not designed to try and
recreate conditions experienced in vivo in the clinic. The
exposure of the cells to drug for 1 week was longer than the
exposure experienced by a cell in vivo and the doses used
were at times superphysiological. With these assays an
attempt was made to understand the basic mechanisms
occurring in the cell which may be causing the difference in
resistance observed. This particular assay was carried out on
three separate occasions.
Immunohistochemical analysisfor P53protein
Asynchronous log phase cultures of the KMS, KMST and
KN-NM cell lines were harvested and 1 x 107 cells were
resuspended in 10% formalin solution for 4 h. The cells were
then pelleted and embedded in agar before being placed in a
tissue cassette for tissue processing. The pellets were pro-
cessed overnight before being paraffin embedded. Sections
(4gm) were then cut on a microtome and mounted on
poly-L-lysine-coated microscope slides. The sections were
then dewaxed in xylene, dehydrated in alcohol and mic-
rowaved for 15 min in citrate buffer pH 6.0 to aid antigen
retrieval. Any endogenous peroxidase activity was blocked by
immersing the slides in 3% hydrogen peroxide solution for
30 min. The Ab6 (Oncogene Science) mouse DOI clone
(Vojtesek et al., 1992) anti-p53 antibody diluted to 2 ig ml-'
in Tris-buffered saline (TBS) was then applied to each section
and incubated at room temperature for 1 h. With 2 x 5 min
washes in TBS between each step the following reagents were
applied to the sections for the indicated lengths of time: goat
anti-mouse biotinylated secondary antibody, 30 min (Vectas-
tain); ABC avidin-biotin complex, 30 min (Vectastain); DAB
solution, 10 min; Meyer's haemotoxylin solution, 30 s. Slides
were mounted with DPX and viewed under a light micro-
scope. Brown nuclear coloration indicated elevated levels of
p53 protein.
Assessment ofcell growth and apoptosis
Test cells were plated at a density of 5 x 105 per 75 cm tissue
culture flask. Two flasks were seeded per drug concentration.
The medium was removed 24 h later and replaced with the
corresponding drug-containing medium at the relevant drug
concentrations. Every 24 h thereafter, the medium was
removed and spun at 1500 r.p.m. for 5 min to pellet any
detached cells before being returned to its respective flask for
further incubation. The 'detached cell pellet' was resuspended
in 20 LI of medium. A 4ftl sample of this suspension was
taken and added to 4 jI of trypan blue and placed on a
haemocytometer counting chamber to obtain a count of the
number of detached cells. Another 4jil sample was added to
4fL of acridine orange on a microscope slide and viewed
under a fluorescent microscope at an exciting wavelength of
490 nM (Evans and Dive, 1993). Five horizontal fields were
viewed and the number of cells identified as apoptotic, viable
and 'ghost' were counted. The number of apoptotic cells was
expressed as a percentage of all the detached cells and this
figure was used to adjust the haemocytometer cell count to
give a final estimation of the total number of apoptotic cells
in that sample. The ghost cell count was ignored in the final
calculation because, although these cells had most likely been
through the process of apoptosis, they were not at the time
ofmeasurement and hence not a true reflection of the level of
apoptosis at that time.
Twenty flasks per cell line were run in parallel in order to
determine the growth curve for the same cell population over
the measured period and to enable the number of apoptotic
cells at each dose to be expressed as a percentage of the total
cell population. These flasks were incubated in identical con-
ditions and trypsinised for counting every 48 h from time 0
to day 8 of the experiment. All experiments were carried out
on at least three separate occasions and the results presented
are of data from one representative experiment.
Measurement ofcell cycle distribution
The cell cycle distributions of the trypsinised monolayers (but
not detached cells) were measured on days 3 and 6 of the
experiment. Cell samples for flow cytometry were fixed in 1%
paraformaldehyde and 1% Triton X-100 for 10min before
being washed and resuspended in phosphate-buffered saline
(PBS). Propidium iodide (PI) (20jtl of a 2.5 mgml1 solution
in PBS) and RNAse (10itl of a 10 mgml' solution) were
added to 5 x I05 cells 500,l-I PBS for 30 min at 37°C. The
position of cells in the cell cycle can be estimated as a
function of their DNA content. Propidium iodide was used
to stain the DNA of 20000 cells and the red fluorescence
produced on excitation with an argon ion laser was analysed
using a Coulter Epics XL flow cytometer. Cytograms of
DNA peak vs the area of DNA signal were produced for
each cell sample. The single cell population was enclosed in a
gate and from these data DNA histograms were generated.
Cells in GI, as well as G2 + M cells, have DNA contents,
equivalent to DNA ploidy indices 1.0 and 2.0 respectively.
The DNA content doubles during S-phase of the cell cycleand therefore an estimation of the number of cells between
the GI and G2/M peaks gives an indication of the number of
cells passing through the S-phase. Regions were assigned to
each histogram which were thought to best represent the GI,
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S- and G2/M phases for each cell line. From these regions the
percentage of cells in each phase of the cell cycle was cal-
culated. The position of the cytogram gates and the histog-
ram regions were set on the control sample for each cell line
b
d
f
Figure 1 Immunohistochemical localisation of p53 protein in the series of human embryo fibroblast cell lines. Cell pellets were
fixed in formalin, embedded in paraffin and cut into 4 iM sections. Sections were stained for p53 protein with the Ab6 DOI
antibody (Oncogene Science) and detected using a biotinylated secondary antibody and avidin-biotin immunoperoxidase detection
system as recommended by the manufacturer (Vectastain). Negative control sections were prepared by omitting the p53 antibody to
assess background peroxidase staining. (a) KMS normal fibroblast cell line with antibody. (b) KMS without antibody. (c) KMST
immortalised fibroblast cell line with antibody. (d) KMST without antibody. (e) KN-NM tumorigenic cell line with antibody. (f)
KN-NM without antibody.Drug resistance as a function of cllocyledelay
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and were not altered for any of the subsequent drug-treated
cell samples. This experiment was carried out on at least
three separate occasions and at various other time points
after drug addition. The data presented are from one
representative experiment.
Results
P53 status ofthe three cell lines
The ABC peroxidase staining method was used to stain any
p53 protein present in the cell nucleus (Figure 1). Brown
coloration in the nucleus indicated the presence of p53 pro-
tein. Overexpression or stabilisation ofthe p53 protein results
in levels that are detectable with immunohistochemistry.
(Finlay et al., 1988; Gannon et al., 1990; Iggo et al., 1990).
Apart from slight background staining, the KMS cell line
showed no signs of p53 protein overexpression, suggesting
that this cell line possessed wild-type p53 function (Figure la
and b). This was in contrast to both the KMST and KN-NM
cell lines which showed definite brown nuclear staining,
indicating p53 overexpression/stabilisation and possible dis-
ruption of p53 wild-type function (Figure Ic-f).
Effect ofdifferent S-FU drug concentration on cell survival
For all three cell lines the colonies that survived the increas-
ing concentrations of 5-FU were scored after 3 weeks of
incubation, expressed as a percentage of the number of col-
onies on control drug-free plates and plotted against increas-
ing drug concentration. It can be observed that the normal
KMS cell line is more sensitive to 5-FU than the KMST or
KN-NM cell line (for representative data from one experi-
ment see Figure 2). No difference in resistance was apparent
between the KMST and the KN-NM cell lines.
Growth ofcell lines in thepresence ofincreasing concentrations
ofS-FU
The differences in resistance observed in the colony-forming
assay were supported by the growth curves obtained for each
of the cell lines at the three different drug concentrations (for
representative data from one experiment see Figure 3a, b and
c). The normal KMS cell line in control drug-free medium
proliferated in a normal fashion with a doubling time of
around 48 h and reached confluence by days 7-8 with a
saturation cell density of 5.5 x 106 cells. At drug concentra-
tions of 1 x 10- M and 1 x 10-4 M 5-FU no proliferation or
cell detachment was apparent and the cell number stayed at a
constant level until day 8 at approximately 5 x 105 cells. At a
drug concentration of 1 x 10' M 5-FU the cell number
stayed constant until approximately day 4 and then began to
decrease, reaching a negligible cell level by day 8. The
immortalised KMST cell line reached a saturation cell den-
sity of 7.4 x 106 cells by day 8. Unlike KMS, growth of the
KMST cell line was apparent at a drug concentration of
1 x 10' M 5-FU. As with KMS, the KMST population
appeared to remain static at a drug concentration of 1 x 10-4
M. At a drug concentration of 1 x 10-3 M the population
number decreased after day 4 to reach a negligible level by
day 8. The tumorigenic, KN-NM, N-ras-transformed cell line
showed the highest level ofproliferation ofall three cell lines,
with a doubling time of approximately 36h. However, no
difference in resistance was apparent when compared with
the KMST cell line (Figure 2). The growth rate of the
KN-NM cell line was rapid, reaching a saturation cell density
of approximately 1.2 x 107 cells by day 6. Increased growth,
in terms of increased cell numbers, was apparent when com-
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Figure 2 Intrinsic 5-FU sensitivities of the three different cell
lines in DMEM supplemented with 10% fetal calf serum. *,
KMS normal fibroblasts; *, KMST immortalised fibroblasts; A,
KN-NM tumorigenic cells. These data are taken from one
representative experiment. Each point represents the mean of five
plates.
Figure 3 Growth curves for the three cell lines in the presence of
differing concentrations of 5-FU. (a) KMS normal fibroblasts. (b)
KMST immortalised fibroblasts. (c) KN-NM tumorigenic fibro-
blasts. 0, Control; 0, 1 x 10-5 M; A, X 10-4 M; A, I X 10-3
M, 5-FU. Results shown are of one representative repeat experi-
ment out of three.
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1 AA^ .pared with the KMST cell line at a drug concentration of
1 X 10-5 M 5-FU. At 1 x 10-' M 5-FU, as with the KMS and
KMST cell lines, there was no increase in population size and
a concentration of 1 x 10-' M resulted in a decrease in
population size after day 4 to negligible cell levels by day 8.
These data clearly demonstrate the differences in resistance
of the three cell lines to 5-FU administration. The major
difference can be observed (Figure 3) at a dose of 1 x 10-5 M
5-FU with no growth of the normal KMS cell line in com-
parison with growth of the immortalised KMST and the
tumorigenic KN-NM cell lines. Repeated experiments con-
sistently demonstrated this pattern.
Levels ofapoptosis in the three cell lines
Following initial experiments to establish the levels and rates
of cell death, apoptosis was measured every 24 h for all three
cell lines for a period of 8 days following drug addition. The
drug was not removed from the medium at any time during
this period. The control untreated cell populations showed
levels of apoptosis ranging from negligible at<0.15% of the
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total cell population in the KMS cell line to higher levels of
1.5 and 2.5% for KMST and KN-NM cell lines respectively
(Figure 4). High levels ofapoptosis were observed in all three
cell lines 6 days after continuous exposure to the highest drug
concentrations of 1 x 10-3 M 5-FU, at levels of 52% of the
total cell population in KMS, 51% in KMST and 42% in
KN-NM (data from one representative experiment). How-
ever, a difference in the level of apoptosis was observed
between the KMS normal cell line and the KMST and
KN-NM cell lines in response to lower concentrations of
5-FU. At drug concentrations of 1 x 0-5 and 1 x 10-4 M,
the KMS cell line showed negligible levels of apoptosis
(Figure 4). These levels were in contrast to those seen in the
KMST and KN-NM cell lines, at the same drug concentra-
tions, which both demonstrated increasing levels of apoptosis
through the 8 day period. The level of apoptosis appeared to
increase in a dose-dependent manner with both the KMST
and KN-NM cell lines reaching levels of 8.2% and 17.8%
respectively, by day 8 at a concentration of 1 x 10-4 M
(Figure 4).
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Figure 4 Levels of apoptosis expressed as a percentage of the
total cell population. (a) KMS normal fibroblasts. (b) KMST
immortalised fibroblasts. (c) KN-NM tumorigenic fibroblasts. 0,
Control; 0, I x 10-5 M; A, I X 10-4 M, 5-FU. The levels of
apoptosis at a concentration of I x 10-3 M 5-FU have been
omitted from the graph as this dose appeared to be universally
toxic and induced high levels of apoptosis in all the cell lines.
Results shown are of one representative repeat experiment out of
three.
Effect on cell cycle
The DNA content of 20 000 cells was measured. The cytog-
rams and histograms for the three cell lines representing the
state of their cell cycles 3 days after continuous exposure to
various concentrations of 5-FU are shown in Figure 5. The
percentage of cells in each phase of the cell cycle are con-
tained in Table I. A time point of 3 days was established
from preliminary experiments and was chosen because of the
relatively slow doubling time of the cell lines and to allow for
the delay in action required by 5-FU. With increasing 5-FU
concentrations up to a level of 1 x 10-' M, the KMS cell line
maintained a definite GI/Go arrest, displaying only a slight
fall in percentage from 81.7% (control) to 76.8%. The
percentage of cells in G2/M phase rose in a dose-dependent
manner reaching a level of 34.8% at 1 x 10-3 M, while the
number of cells in S-phase decreased from 7.1% at control
level to just 2.4% at a 5-FU concentration of 1 x 10-3 M.
This was in contrast to the situation with the KMST and
KN-NM cell lines, which both demonstrated large increases
in the number of cells in S-phase with increasing 5-FU
concentration while the number of cells in GI/Go and G2/M
decreased. The percentage of cells in S-phase rose from a
control level of 13.8 and 7.2 to 37.3 and 29.8 at a drug
concentration of 1 x 10-3 M, for the KMST and KN-NM
cell lines respectively.
Discussion
Previous studies from this group have shown that differences
in the resistance of a series of human embryo fibroblasts to
MTX and PALA can be greatly exaggerated by the involv-
ment of the salvage pathways for purine and pyrimidine
biosynthesis (Kinsella and Haran, 1991; Pickard and
Kinsella, 1995). A similar pattern of increasing resistance
paralleling increasing tumorigenicity was observed for 5-FU,
but as stated previously, was independent ofsalvage pathway
involvement. No change in the resistance to 5-FU was
observed in any of the three cell lines in the presence of the
dipyridamole at a concentration of 5gM. Dipyridamole has
previously been shown to be an effective inhibitor of
nucleoside transport (Berlin and Oliver, 1972; Paterson et al.,
1980; Plagemann and Wolhueter, 1980; Young and Jarvis,
1983; Zhen et al., 1983). A significant increase in the sen-
sitivity of the KMST and KN-NM cell lines was observed
when MTX and PALA were administered in the presence of
dipyridamole (Pickard and Kinsella, 1995).
Immunohistochemical analysis revealed differences in the
levels of p53 protein between the three cell lines. These data
suggested that wild type-p53 function may have been dis-
rupted in the immortalised KMST and the tumorigenic KN-
NM cell lines (Figure 1). Increased p53 protein stability in a
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-- 01Table I Cell cycle data for the 3 cell lines after 72 h of continuous
exposure to the various concentrations of 5-FU
S-FU conc. Cell cycle phase
Cell line (M) % Go/GI %S %G2+ M
KMS (Normal) Control 81.7 7.1 13.1
1 X 0-5 83.5 1.4 14.5
1 X 10-4 76.8 1.8 20.5
1 X 10-3 62.7 2.4 34.8
KMST Control 60.5 13.8 25.3
(Immortal) 1 x 10-5 56.6 12.7 29.9
1 X 10-4 38.4 40.7 20.0
1 X 10-3 44.4 37.3 22.5
KN-NM Control 65.9 7.2 26.4
(Tumorigenic) 1 x 10-5 67.0 10.7 23.2
1 x 10-4 56.0 29.4 14.0
1 X 10-3 53.8 29.8 19.6
cell nucleus was thought, until recently, to correlate directly
with mutation of the p53 gene (Gannon et al., 1990; Iggo et
al., 1990; Baas et al., 1994). This association has recently
been called into question following the publication of a
number of studies suggesting false-positive and negative
results (Borreson et al., 1991; Cripps et al., 1994). It has now
been reported that, as well as mutation, other factors can
stabilise p53 protein and render it non-functional (Vogelstein
and Kinzler, 1992). Interactions with viral proteins, such as
the large T antigen of SV40 (Lane and Benchimol, 1990;
Levine et al., 1991), or interactions with cellular proteins
such as the mdm-2 gene product (Wu et al., 1993) have been
shown to stabilise p53 protein. These observations have now
led to the theory that it is the whole cellular environment
that determines p53 stability and therefore function (Hall and
Lane, 1994). These data suggest that stabilised, immunohis-
tochemically detectable p53 protein, whether created as a
result of mutation or by some other protein interaction, may
have an inactivated or impaired function in the cell. The p53
tumour-suppressor gene product is now thought to play an
important role as a GI to S checkpoint control in the cell
cycle and as a controller of cells entering apoptosis, following
DNA damage (Kastan et al., 1991; Kuerbitz et al., 1992).
DNA strand breaks are thought to be an important factor in
initiating this DNA damage response pathway (Nelson and
Kastan, 1994). It has been postulated that the outcome of
drug therapy will be determined by the response of the cell,
according to its phenotype, rather than by the nature of the
primary drug target interaction alone (Dive and Hickman,
1991). The response of the cell can manifest itself in several
ways including apoptosis (Clarke et al., 1993; Lowe et al.,
1993b, c), cell cycle arrest (Mcllwrath et al., 1994; Nelson
and Kastan, 1994) or drug-induced increases in metastatic
potential (McMillan and Hart, 1987).
This, together with the evidence for differences in p53
functionality between the cell lines, lead us to postulate that
the differences in cell line sensitivity to 5-FU (Figure 2) may
be the result of differing cellular responses to drug-induced
damage. Contrary to expectation, measurement of apoptosis
in the three cell lines showed the normal KMS cell line, with
wild-type p53 protein levels, to apoptose at a lower level than
the more resistant KMST and KN-NM cell lines. From these
data it became clear that the differences in the levels of
apoptosis between the cell lines could not explain the
differences in resistance observed.
Detailed cell cycle analysis showed that the KMS cell line
ceased to proliferate in response to increasing levels of 5-FU
and appeared to be in some type of growth arrest. This was
in contrast to both the KMST and KN-NM cell lines, which
appeared to continue proliferating regardless of the insult.
Representative cytograms and DNA histograms obtained for
the three cell lines after 3 days' exposure to increasing con-
centrations of 5-FU can be observed in Figure 5. This time
point was independent of any influence of growth factor
depletion or contact inhibition on the cell proliferation rate,
as can be observed from the growth curves (Figure 3). All
three cell lines showed classical cell cycle patterns in control
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drug-free medium, with a GI and G2 peak divided by cells in
S-phase. The KMS normal cell line showed a decrease in the
percentage of cells in S-phase with increasing 5-FU concen-
tration, with a G1 arrest predominating at low drug concen-
trations and a G2/M arrest at higher drug concentrations.
This type of response to presumed drug-induced DNA
damage is the classical pattern for wild-type p53 function as
first described by Kastan et al. (1991). Cells that are already
in S-phase at the time of DNA damage continue to progress
through to G2/M, whereas cells in GI do not continue to
enter S-phase. After 1 week of exposure the drug was
removed from the cells. The KMS cells exposed to the two
highest doses of 5-FU showed no signs of further prolifera-
tion and were confirmed to be in permanent growth arrest.
One may predict that the amount of damage in these cells
was at such a high level that the cells were held in a perma-
nent state of growth arrest. Leonardo et al. (1994) have
recently reported a similar permanent growth arrest response
in human fibroblasts following ionising radiation. Thus, in
addition to apoptosis and transient cell cycle arrest, perma-
nent growth arrest may be a third type of cellular damage
response. The immunohistochemical and cell cycle data are
consistent with the KMS cell line having wild-type p53 func-
tion. This is in contrast to the situation seen with both the
KMST and KN-NM cell lines. These cell lines demonstrated
a dramatic increase in the percentage of cells in S-phase with
increasing concentrations of 5-FU. The number of cells in
both G1 and G2/M decreased with increasing 5-FU concent-
rations. These data, along with the KMST and KN-NM
immunohistochemical data, therefore suggest that wild-type
p53 function may have been lost from both these cell lines
and that, especially at high doses of 5-FU, the cell cycle is
well out of control.
The effect of the activated N-ras oncogene on the growth
rate of the KN-NM cell line was easily recognisable (Figure
3). Growth was much more rapid and the cell number
reached a much higher level in 8 days than the KMST cell
line. Although proliferation was increased and colony forma-
tion was more substantial in the tumorigenic KN-NM cell
line this appeared to have no effect on the overall resistance
of the cell population to 5-FU (Figure 2).
In conclusion, these data have demonstrated an association
between cell cycle changes and sensitivity to 5-FU. Normal
cells appear to modulate this response by a permanent G1
arrest, with significant apoptosis only occurring at the highest
doses of 5-FU. Contrary to expectation, the cells tending
towards tumorigenicity underwent higher levels of apoptosis
than the normal cells. This phenomenon may have been
related to increasing levels of 5-FU and presumably DNA
damage in cells lacking cell cycle control, resulting in spon-
taneous apoptosis as a result of a failure in mitosis. In this
series ofexperiments, p53 was not artificially inserted into the
cell lines, however both indirect immunohistochemical and
direct cell cycle evidence suggests that wild-type p53 function
has been lost by the cells tending towards tumorigenicity.
This model is thought to be a good reflection of the situation
actually occurring in vivo, as a cell progresses from its normal
phenotype to one of a tumorigenic cell. These data demon-
strate the effect of loss of cell cycle control, whether p53
dependent or not, in regulating the sensitivity of human cells
to DNA-damaging agents. If cell cycle control is missing, as
in the progression towards malignancy, then increasingly
resistant phenotypes appear to result. Clearly the next
experiments need to be conducted with the use of cells of
known p53 status, employing the use of wild-type and
mutant p53-containing vectors.
Abbreviations
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